durvalumab,carboplatin,pemetrexed,paclitaxel,cisplatin,gemcitabine
astrazeneca
['aegean', 'durva', 'astrazeneca']
 presented the ph iii aegean trial results at #aacr2023.
n=802 pts (durva. (n=400 pts) and pbo (n=399 pts))
efficacy results (n=400 pts): mefs = 11.7 mos, pcr = 17.2%
trial met both of its pe's of improved pcr and efs 
DataZymes is a consulting firm specializing in providing comprehensive competitive intelligence and forecasting services across various pharma segments